Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Clinical trial NCT06888323 · SUSPENDED
Trial details
- NCT number
- NCT06888323
- Sponsor
- National Cancer Institute (NCI)
- Status
- SUSPENDED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-03
- Primary completion
- 2027-12-31
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.